Autumn Rights Medical Guide 2019

MENTAL HEALTH
THE CLOZAPINE HANDBOOK
Stahl’s Handbooks
Jonathan M. Meyer
University of California, San Diego
and Stephen M. Stahl
University of California, San Diego
July 2019
186 x 123 mm 326pp
24 b/w illus.
978-1-108-44746-1 Paperback
£39.99
Real-world and clinical trial data support that clozapine is the only effective
antipsychotic for treatment resistant schizophrenia and other severe
mental illnesses. Clozapine also reduces rates of suicidality, psychiatric
hospitalization and all-cause mortality. However, clozapine is underutilized for
two reasons: misunderstandings of its efficacy benefits and misapprehension
of, limited knowledge or misinformation about the management of treatment
related risks and adverse effects. In response to worldwide efforts to promote
clozapine use, this user-friendly Handbook provides clinicians with evidencebased
approaches for patient management, as well as logical approaches to
the management of clinical situations and adverse effects. It outlines clearly
the rationale for specific management decisions and prioritises the options
based on this logic. This Handbook is designed for use by clinicians worldwide
and is essential reading for all mental health care professionals.
WHY IT WILL SELL
• The increased interest in promoting
greater clozapine use internationally
means this book fills a gap in the market
for clinicians who seek evidence-based
advice on best practices
• Use of clozapine has shown real
world benefits such as a reduction in
suicidality, psychiatric hospitalization
and mortality rates; many clinicians are
unfamiliar with recent improvements in
the understanding of clozapine-related
dosing and adverse effect management
• Provides a logical, evidence-based
framework for important clinical issues,
leading the clinician through the
reasoning process for adverse effect
management and other common clinical
situations
CONTENTS
Preface; 1. Initiating Clozapine; 2. Understanding hematologic monitoring and benign ethnic
neutropenia; 3. Binding profile, metabolism, kinetics, drug interactions and use of plasma levels;
4. Managing constipation; 5. Managing sialorrhea; 6. Managing sedation, orthostasis and
tachycardia; 7. Managing metabolic adverse effects; 8. Managing seizure risk and stuttering; 9.
Fever, myocarditis, interstitial nephritis, DRESS, serositis and cardiomyopathy; 10. Eosinophilia,
leukocytosis, thrombocytopenia, thrombocytosis, anemia, hepatic function abnormalities; 11.
Managing enuresis and incontinence, priapism, venous thromboembolism, neuroleptic malignant
syndrome, tardive dyskinesia and obsessive compulsive disorder; 12. The efficacy story: treatment
resistant schizophrenia, psychogenic polydipsia, treatment intolerant schizophrenia, suicidality,
violence, mania and Parkinson’s disease psychosis; 13. Addressing clozapine positive symptom
nonresponse in schizophrenia spectrum patients; 14. Discontinuing clozapine and management
of cholinergic rebound; 15. Special topics: child and adolescent patients, elderly patients, patients
with intellectual disability, pregnancy and risk for major congenital malformation, lactation,
overdose, postmortem redistribution; Index.
ADDITIONAL INFORMATION
Level: medical specialists/consultants, professionals
Series: Stahl’s Essential Psychopharmacology Handbooks
www.cambridge.org/rights
foreignrights@cambridge.org
13
41583.indd 13 05/09/2019 10:12